App-Quantinova.ai

IDH-1/2 mutations and associated oncometabolite 2-hydroxyglutarate (2-HG) in solid tumors.

Nazanin Fallah-Rad - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Hepatitis B and C positivity rates in solid tumors and reactivation rates due to cytotoxic chemotherapy.

Deniz Tural - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Relationship of pleural fluid analysis with outcomes in cancer patients.

Ioana Bonta - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

RNA expression analysis of TCGA data and the limits of genomic features in tumor profiling.

Ryan Bloom - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Genomic landscape of defective DNA damage response and repair mechanisms (DDR) across cancer types.

Min Yuen Teo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Reprogramming of cell signaling in response to MEK inhibition in non-small cell cancer (NSCLC).

Yasir Elamin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Refametinib

Development of personalized cancer immunotherapy by integrated genomics.

Yataro Daigo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A targeted next generation sequencing assay to characterize relevant cancer variants in solid tumor samples.

Vinay Kumar Mittal - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Optomagnetic imaging spectroscopy (OMIS) as a novel method in the characterization of cervical smears.

Khalil Razvi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Analysis of RSPO gene expression in solid tumors.

Ana Vivancos - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Use of next generation sequencing and quantitative mass spectrometry to determine HER2 status.

Pedram Razavi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Evaluation of the prognostic value of RANK, RANKL, OPG and OPN mRNA expression in high-risk early breast cancer patients treated with anthracycline-containing adjuvant chemotherapy.

Eleni Timotheadou - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Epirubicin

PIK3CA mutation analysis in Chinese patients with solid tumors.

Ling Xu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A Pilot Study of the Impact of a Single Dose of Zolendronic acid on Biomarkers in Breast Cancer.

May Thet Cho - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Zolendronic acid

Exploratory investigation of PSCA-protein expression in primary breast cancer and its clinical relevance.

Pauline Wimberger - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Correlation of loss of ataxia-telangiectasia-mutated protein expression with poor prognosis and benefit from anthracycline containing adjuvant chemotherapy in breast cancer.

Koung Jin Suh - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Differing pattern of biological characteristics of early operable primary breast cancer according to age.

Binafsha Manzoor Syed - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

DNA repair defect and RAS mutation in Schistosoma mansoni-associated colorectal cancer patients: Carcinogenesis steps or mere coincidence?

Gustavo Fernandes Godoy Almeida - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Influence of ADIPOQ rs266729 G/C gene polymorphism on serum adiponectin and correlation with metabolic syndrome in colorecatal cancer patients.

Rosa Divella - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Evaluation of the concordance between centrosome amplification and mitotic frequency between patient tumors and cultured cancer cells.

Karuna Mittal - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

N/A

Filters

41730 Abstracts